Literature DB >> 8683153

CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes.

G J Wolbink1, M C Brouwer, S Buysmann, I J ten Berge, C E Hack.   

Abstract

The in vivo function of C-reactive protein (CRP) is unknown. Among the in vitro functions assigned to CRP is the ability to activate complement via the classical pathway. To date, there is no evidence supporting that CRP exerts this function in vivo. We here show a novel approach to assess CRP-mediated complement activation in vivo, which is based on the property that activated complement factors C3 and C4 fix to CRP during complement activation induced by this acute phase protein. We developed specific ELISAs for complexes between CRP and C4b, C4d, C3b, or C3d. We established that in vitro complement-CRP complexes were formed only during CRP-dependent activation, and not during activation by other activators, even in the presence of high CRP levels. Circulating levels of complement-CRP complexes were undetectable in normal donors, but significantly increased in nine patients following implantation of a renal allograft. Importantly, levels of complement-CRP complexes did not change in these patients upon a bolus infusion of mAb OKT3, which induces activation of the classical complement pathway, demonstrating in vivo that complement-CRP complexes are not formed during CRP-independent activation of complement, even when CRP is elevated. We conclude that measurement of complement-CRP complexes provides a suitable tool to study CRP-mediated activation of complement in vivo. Furthermore, increased levels of these complexes occur in clinical samples, indicating that CRP may induce activation of complement in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683153

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

Review 1.  C-reactive protein as a pro-inflammatory mediator in cardiovascular disease by its ability to activate complement: additional proof and hypothetical mechanisms.

Authors:  W K Lagrand; R Nijmeijer; H W M Niessen; C A Visser; W Th Hermens; C E Hack
Journal:  Neth Heart J       Date:  2002-04       Impact factor: 2.380

2.  Generation of C-reactive protein and complement components in atherosclerotic plaques.

Authors:  K Yasojima; C Schwab; E G McGeer; P L McGeer
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease.

Authors:  Colm Cunningham; David C Wilcockson; Delphine Boche; V Hugh Perry
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 4.  Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis.

Authors:  Molly D Magnano; Mark C Genovese
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

5.  Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.

Authors:  A Familian; A E Voskuyl; G J van Mierlo; H A Heijst; J W R Twisk; B A C Dijkmans; C E Hack
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

Review 6.  C-reactive protein, inflammation, and innate immunity.

Authors:  R F Mortensen
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 7.  Complement and autoimmunity.

Authors:  Eleonora Ballanti; Carlo Perricone; Elisabetta Greco; Marta Ballanti; Gioia Di Muzio; Maria Sole Chimenti; Roberto Perricone
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

8.  Relationship between the plasma concentration of C-reactive protein and severity of peripheral arterial disease.

Authors:  Joaquin De Haro; Francisco Acin; Francisco Jose Medina; Alfonso Lopez-Quintana; Jose Ramon March
Journal:  Clin Med Cardiol       Date:  2008-12-23

9.  Effects of C-reactive protein and pentosan polysulphate on human complement activation.

Authors:  Andis Klegeris; Edith A Singh; Patrick L McGeer
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

Review 10.  Novel mechanisms of action of the biologicals in rheumatic diseases.

Authors:  Cecilia Beatrice Chighizola; Ennio Giulio Favalli; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.